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Abstract
Background: Model checking approaches were applied to biological pathway validations around
2003. Recently, Fisher et al. have proved the importance of model checking approach by inferring
new regulation of signaling crosstalk in C. elegans and confirming the regulation with biological
experiments. They took a discrete and state-based approach to explore all possible states of the
system underlying vulval precursor cell (VPC) fate specification for desired properties. However,
since both discrete and continuous features appear to be an indispensable part of biological
processes, it is more appropriate to use quantitative models to capture the dynamics of biological
systems. Our key motivation of this paper is to establish a quantitative methodology to model and
analyze in silico models incorporating the use of model checking approach.
Results: A novel method of modeling and simulating biological systems with the use of model
checking approach is proposed based on hybrid functional Petri net with extension (HFPNe) as the
framework dealing with both discrete and continuous events. Firstly, we construct a quantitative
VPC fate model with 1761 components by using HFPNe. Secondly, we employ two major biological
fate determination rules – Rule I and Rule II – to VPC fate model. We then conduct 10,000
simulations for each of 48 sets of different genotypes, investigate variations of cell fate patterns
under each genotype, and validate the two rules by comparing three simulation targets consisting
of fate patterns obtained from in silico and in vivo experiments. In particular, an evaluation was
successfully done by using our VPC fate model to investigate one target derived from biological
experiments involving hybrid lineage observations. However, the understandings of hybrid lineages
are hard to make on a discrete model because the hybrid lineage occurs when the system comes
close to certain thresholds as discussed by Sternberg and Horvitz in 1986. Our simulation results
suggest that: Rule I that cannot be applied with qualitative based model checking, is more
reasonable than Rule II owing to the high coverage of predicted fate patterns (except for the
genotype of lin-15ko; lin-12ko double mutants). More insights are also suggested.
Conclusion: The quantitative simulation-based model checking approach is a useful means to
provide us valuable biological insights and better understandings of biological systems and
observation data that may be hard to capture with the qualitative one.
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Background
Model checking is a successful method for automatic ver-
ification of software and reactive systems [1], which is
usually applied to ensure consistency and correctness of
designed models. Practiced verification methods in most
cases are still simple simulation and testing. While simple
simulation and testing provide a part of the possible
results of a model, model checking can conduct an
exhaustive exploration of all possible behaviors [1-4].
Among the features, one merit of using model checking is
that it is possible to verify a set of rules defined by users.
Recently, the size of targeting network becomes enlarged and
difficult to check all rules and their combinations by each
user, especially, biologist. To solve this, around 2003, several
attempts were launched to apply model checking
approaches to biological pathway validations [5-12]. With
the aid of model checking approach, one can obtain answers
to questions such as "what is the probability that the gene
finally expressed?" and "does this reaction always lead to
DNA fragmentation?" In 2007, Fisher et al. proved the
importance of model checking approach by inferring the
new regulation of inductive and lateral signaling crosstalk of
C. elegans and confirming the regulation with biological
experiments [9]. The approach was applied on a discrete
model by using one of the model checking languages named
reactive modules [13]. However, quantitative properties (e.g.
continuous feature) are also important in biological proc-
esses, such as the concentration of proteins and the reaction
rates. Thus, it is desirable to deal with both discrete and con-
tinuous features in the model (called hybrid model). From this
fact, the next challenge is to apply the model checking
approach to such hybrid models. Several hybrid models
have been applied to biological pathway modeling, e.g.
hybrid automata [6], π-calculus [14], ordinary differential
equations (ODEs) [15], and hybrid functional Petri nets
(HFPN) [16] and its extension (HFPNe) [17,18]. Among
them, HFPNe and its related concepts have been accepted as
a formal modeling method due to potential advantages of
HFPNe possessing intuitive graphical representation and
capabilities for mathematical analysis [19-23].
We use HFPNe to quantitatively model C. elegans vulval
development mechanism, which best meets the features of
biological processes. We have been developing an HFPNe
based software "Cell Illustrator" [24,25] for modeling and
simulating biological pathways [17,18,26]. It has been suc-
cessfully employed to develop and analyze some pathway
models for gene regulatory networks, metabolic pathways,
and signaling pathways [16,27-31]. In this paper, Cell Illus-
trator is used as a software tool to model and simulate this
complicated biological system in C. elegans.
The paper is organized as follows: In Methods, we first
present an introduction of HFPNe and biological back-
ground of VPC fate determination mechanism. We dem-
onstrate how to construct VPC fate model by using HFPNe
afterwards. When determining cell fate from biological
points of view, several biological fate determination rules
can be considered. We thus employ two major biological
fate determination rules – Rule I and Rule II – to the VPC
fate model. Two rules are used to determine the cell fate
from two viewpoints – temporal interval and temporal
order – of time course expression of cell fate candidates.
Next, we conduct 10,000 simulations for each of 48 sets
of different genotypes which are the combination of four
mutants and AC (anchor cell). The simulation procedures
such as noise parameters, high-speed simulation engine,
and the emulation of the temporal stimulations are also
described. Finally, we examine the consistency and cor-
rectness of the VPC fate model, and evaluate proposed
two rules by comparing with three simulation targets con-
sisting of predicted fate patterns obtained from in silico
and in vivo experiments. In Results and Discussion, our
simulation results suggest that Rule I on the temporal
interval is more reasonable than Rule II owing to the high
coverage of predicted fate patterns (except for lin-15ko; lin-
12ko double mutants), (ii) for the lin-15ko; lin-12ko dou-
ble mutants, the coverage will be considerably aug-
mented, if the number of animal population is increased
in the in vivo experiments, and (iii) unmatched fate pat-
terns of lin-15ko and ac-; lin-15ko, still have the possibility
to be examined in in vivo experiments by enlarging animal
numbers. More insights concerning the hybrid lineage are
also suggested and discussed. The final section concludes
the paper and addresses the contributions of the work.
Methods
Figure 1(a) illustrates the procedure overview of Methods.
Briefly, starting from an introduction of HFPNe and VPC
induction mechanisms, we first show the processes of
constructing HFPNe-based VPC fate model (VPC fate
model for short). We then employ two major biological
fate determination rules to the VPC fate model from dif-
ferent viewpoints: temporal interval and temporal order.
Finally, we execute 480,000 simulations in total for differ-
ent genotypes by comparing with three simulation targets
(i.e., JA, ST, and STA) (see Figure 1(b)). JA consists of fate
patterns obtained by using model checking approach
(with MOCHA);  ST  is the fate patterns summarized by
Sternberg and Horvitz [32]; and STA is the fate patterns
derived from [32] including hybrid lineage data. The aims
of the simulation are: (i) to investigate predicted fate pat-
terns variations of each genotype, and (ii) to evaluate two
rules employed to VPC fate model.
Modeling biological pathways with hybrid functional Petri 
net with extension (HFPNe)
Brief introduction of HFPNe: an enhanced Petri net for modeling 
biological interactions
Petri net is a network which consists of place, transition,
arc, and token. A place can hold tokens as its content. ABMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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(a) Procedure overview of the Methods section Figure 1
(a) Procedure overview of the Methods section. (b) Schematic view of three simulation targets.
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transition has arcs coming from places and arcs going out
from the transition to some places. A transition with these
arcs defines a firing rule in terms of the contents of the
places where the arcs are attached [33].
Due to the limitation of conventional Petri net and more
requirements in modeling, Matsuno et al. have defined
hybrid functional Petri net (HFPN for short) in 2003 [16].
However, when modeling biological pathways, it has
been noticed that several useful extensions should be
applied for modeling and simulating more complicated
biopathway processes (e.g., activities of enzymes for a
multi-modification protein) and other biological proc-
esses that are not normally treated in biological pathways
(e.g., alternative splicing and frameshifting) [18]. There-
fore, Nagasaki et al. have proposed a new enhanced Petri
net architecture hybrid functional Petri net with extension
(HFPNe) in 2004. They have firstly used the new termi-
nology in HFPNe to bridge the gap between the research-
ers of computer science and biology. In other words, the
terms of place, transition, arc, and token are named as
entity, process, connector, and content respectively.
HFPNe can deal with three types of data – discrete, contin-
uous, and generic – and comprises three types of elements
– entities, processes, and connectors – whose symbols are
illustrated in Figure 2. A discrete entity holds a positive
integer number of content. A discrete process is the same
notion as used in the traditional discrete Petri net [33]. A
continuous entity holds a nonnegative real number as
concentration of a substance such as mRNA and protein.
A continuous process is used to represent a biological
reaction such as transcription and translation, at which
the reaction speed is assigned as a parameter. A generic
entity can hold various kinds of types including object,
e.g., the string of nucleotide base sequence. A generic
process can deal with any kind of operations (e.g., alterna-
tive splicing and frameshifting) to all types of entities.
Connectors are classified into three types: process connec-
tor, associate connector, and inhibitory connector. Proc-
ess connector connects an entity to a process or vice versa.
Associate or inhibitory connector represents a condition
and is only directed from an entity to a process. Each of
process connector from an entity, associate connector,
and inhibitory connector has a threshold by which the
parameter assigned to the process at its head is controlled.
A process connector from an entity or an associate connec-
tor (an inhibitory connector) can participate in activating
(repressing) a process at its head, as far as the content of
an entity at its tail is over the threshold. For either of asso-
Basic elements of HFPNe and examples of biological icons in Cell Illustrator Figure 2
Basic elements of HFPNe and examples of biological icons in Cell Illustrator. In Cell Illustrator [24-26], HFPNe ele-
ments are replaced with the biological icons defined in the Cell System Ontology [47]. This replacement makes the HFPNe 
model of a biological pathway more comprehensible (see [17] for details).
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ciate or inhibitory connectors, no amount is consumed
from an entity at its tail. The followed section only gives
the mathematic definitions of HFPNe. For the detailed
formal definition and properties of HFPNe, the readers
are suggested to refer to [18].
Basic definitions of HFPNe
For modeling complex biological processes intuitively, we
are required to deal with various kinds of biological infor-
mation, e.g. the density of molecules, the number of mol-
ecules, sequences, molecular modifications, binding
location, localization of molecules, etc. To cope with this
feature in biological system modeling, we introduce types
for biological entities and processes.
The set T of types is defined by the following abstract syn-
tax:
Then, for θ ∈ T, we define the domain D(θ) of θ as follows:
1. D(boolean) = {true, false}, D(integer) = Z (the set
of integers), D(integer+) = N (the set of nonnegative
integers),  D(real) = R  (the set of real numbers),
D(real+) = R≥0 (the set of nonnegative real numbers),
D(string) = S (the set of strings over some alphabet).
2. D(pair(θ1, θ2)) = D(θ1) × D(θ2).
3. D(listθ) = ∪k ≥ 0 D(θ)k.
4. D(object(θ1, • , θn)) = D(θ1) × •  × D(θn).
For convenience, we denote D* = ∪θ ∈ TD (θ).
Let E be a finite set. A type function for E is a mapping τ: E
→ T. For e ∈ E, τ(e) is called the type of e. A marking of E is
a mapping M : E → D* satisfying M(e) ∈ D(τ(e)) for e ∈
E. For e ∈ E, M(e) called the mark of e. We denote by  the
set of all markings of E. We can regard  as the set ∏e∈E
D(τ(e)).
Consider a function f :  → R. For a subset F ⊆ E and an ele-
ment v ∈ ∏e ∈ F D(τ(e)), let f [F = v]: ∏e ∈ E-F D(τ(e)) → R
be the function obtained from f by restricting the value for
F to v, i.e. f [F = v](z) = f(z, v) for z ∈ ∏e ∈ E-F D(τ(e)). Let F
be a subset of E such that e ∈ F satisfies D(τ(e)) = R or R≥
0. We say that the function f is continuous for F if f [E - F =
v]: ∏e ∈ F D(τ(e)) → R is continuous on ∏e ∈ F D(τ(e)) for
any v ∈ ∏e ∈ E-F D(τ(e)).
Based on the above terminology, we define the notion of
hybrid functional Petri net with extension (HFPNe). The
basic idea of HFPNe is two-fold. The first is to introduce
types with which we can deal with various data types. The
second is to employ functions of marking f(M) to deter-
mine the weight, delay, and speed, etc. which control the
system behavior. In the following definition, we use dif-
ferent names instead of place, transition, arc, etc. which
are conventionally used in Petri net theory since biologi-
cal system modeling requires more intuitive names for
representing biological entities and processes.
[Definition 1] We define a hybrid functional Petri net with
extension (HFPNe) H = (E, P, h, τ, C, d, α) as follows:
1. E = {e1, • , en} is a non-empty finite set of entities and
P = {p1, • , pm} is a non-empty finite set of processes,
where we assume E ∩ P = ∅.
2. h : E ∪ P → {discrete, continuous, generic} is a map-
ping called the hybrid function. Terms "discrete" and
"continuous" correspond to those in hybrid Petri net
[16] and "generic" is a newly introduced name which
can be of any type in T. A process p ∈ P with h(p) = dis-
crete (resp., continuous, generic) is called a discrete
process  (resp.,  continuous process,  generic process). An
entity e ∈ E with h(e) = discrete (resp., continuous,
generic) is called a discrete entity (resp.,  continuous
entity, generic entity).
3. τ: E → T is a type function for E such that τ(e) = inte-
ger+ if e is a discrete entity, and τ(e) = real+ if e is a con-
tinuous entity.
4. C = (EP, PE, a, w, u) consists of subsets EP ⊆ E × P
and PE ⊆ P × E. An element in EP ∪ PE is called a con-
nector. Each connector has a connector type which is
given by a mapping a : EP ∪ PE → {process, associate,
inhibitor} called the connector type function which sat-
isfies the conditions: (i) a(c) = process for c ∈ PE. (ii)
All connectors c = (e, p) ∈ EP satisfy the conditions in
Table 1(a) and all connectors c = (p, e) ∈ PE satisfy the
conditions in Table 1(b). A connector c = (e, p) ∈ EP is
called a process connector (resp., an associate connector,
an inhibitory connector) if a(c) = process (resp., associ-
ate, inhibitor). "Process connector", "associate con-
nector" and "inhibitory connector" correspond to
normal arc, test arc and inhibitory arc, respectively. For a
connector c = (p, e) ∈ PE, a(c) = process by definition
and we also call it a process connector. We say that a con-
nector  c  = (e,  p)  ∈  EP  is  discrete  (resp.,  continuous,
generic) if p  is a discrete process (resp., continuous
process, generic process). In the same way, we also say
that c = (p, e) ∈ PE is discrete (resp., continuous, generic)
〈〉= + + type :: || || || || || || boolean integer integer real real string
p pair list object (,) | | | | (, ,) 〈〉 〈〉 〈〉 〈〉 〈〉 type type type type type L . .BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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if p is a discrete process (resp., continuous process,
generic process). Let  be the set of all markings of E and
let F be the set of continuous entities in E. Then we
denote   = {f |f :  → N},   = {f |f :  →
R≥ 0 is continuous for F},   = {f |f :  → D*}, and
 = {f |f :  → {true, false}}.
Then w and u are given as follows:
(a) w :   is a func-
tion called the activity function such that for a connector c
∈  EP  (i)  w(c)  ∈   if  c  is discrete, (ii) w(c)  ∈
 if c is continuous, (iii) w(c) ∈   if  c is
generic. For a connector (e, p), w(e, p) be used as a func-
tion giving the threshold in discrete and continuous cases
and the condition in generic case which is required for
enabling the process p.
(b)  u  :   is a
function called the update function which satisfies the fol-
lowing conditions: For a connector c ∈ EP ∪ PE, let c = (e,
p) ∈ EP or c = (p, e) ∈ PE. (i) u(c) ∈   if  c is discrete.
(ii) u(c) ∈   if  c is continuous. (iii) If c is generic,
then u(c) is a function in   such that u(c)(M) is in
D(τ(e)) for any marking M ∈ . For a connector c = (e, p) or
c = (p, e), u(c) is used as a function which will update the
mark of e.
5. d : Pdiscrete →   is a mapping called the
delay, where Pdiscrete is the set of discrete processes in P.
For a discrete process p, d(p):  → R≥0 is called the delay
function of p.
6. α > 0 is a real number called the generic time. The
generic time is used as the clock for generic processes.
We introduce a parameter t ∈ R≥ 0 called the time to a
hybrid functional Petri net with extension H = (E, P, h, τ,
C, d, α). Given a marking I called the initial marking, we
define a marking M(t) called the marking at time t and a
marking Mr(t) called the reserved marking at time t for t ≥ 0
in the following way.
By convention, we denote M(e, t) = M(t)(e) and Mr(e, t) =
Mr(t)(e) for e ∈ E. We define  (t) by  (e, t) = M(e, t) -
Mr(e, t) for discrete and continuous entities and  (e, t) =
M(e, t) for generic entities e.
First, we define M(0) = I, Mr(e, 0) = 0 for all discrete and
continuous entities e. For all generic entities e, Mr(e, t) =
null (the empty list) for any t ≥ 0. For t > 0, we define M
(t) and Mr(t) in the following way.
Ddiscrete Dcontinuous
Dgeneric
Dboolean
EP →∪ ∪ DD D discrete continuous boolean
Ddiscrete
Dcontinuous Dboolean
EP PE ∪→ ∪ ∪ DD D discrete continuous generic
Ddiscrete
Dcontinuous
Dgeneric
Dcontinuous
% M % M
% M
Table 1: The conditions of the connector type
connector type process connector associate or inhibitory connector
process type discrete continuous generic discrete continuous generic
(a) entity discrete X - X X X X
type continuous X X X X X X
generic - - X X X X
connector type process connector associate or inhibitory connector
process type discrete continuous generic discrete continuous generic
(b) entity discrete X - X - - -
type continuous X X X - - -
generic X X X - - -
Table 1: (a) For a connector c = (e, p) ∈ EP, the entity type h(e), the process type h(p) and the connector type a(c) must satisfy the following 
conditions, where X means that the connection is allowed and – means that the connection is not allowed. (b) For a connector c = (p, e) ∈ PE, the 
connector type a(c) is process by definition. The entity type h(e) and the process type h(p) must satisfy the following conditions, where X means 
that the connection is allowed and – means that the connection is not allowed.BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
Page 7 of 35
(page number not for citation purposes)
For a process p ∈ P at time t, if the following conditions
are satisfied, then the process p is said to be enabled at time
t. Otherwise the process is said to be disabled at time t.
1. If p is a discrete process, then for all connectors c =
(e, p) ∈ EP the following conditions hold:
(a) (e, t) ≥ w(e, p)(M(t)) if a(c) ≠ inhibitor.
(b) (e, t) <w(e, p)(M(t)) if a(c) = inhibitor.
2. If p is a continuous process, then for all connectors
c = (e, p) ∈ EP the following conditions hold:
(a) (e, t) ≥ w(e, p)(M(t)) if a(c) ≠ inhibitor.
(b) (e, t) ≤ w(e, p)(M(t)) if a(c) = inhibitor.
3. If p is a generic process, then for all connectors c =
(e, p) ∈ EP the following conditions hold:
(a) w(e, p)( (t)) = true if a(c) ≠ inhibitor.
(b) w(e, p)( t)) = false if a(c) = inhibitor.
If a disabled process turns to be enabled at time t, the
process is said to be triggered at time t. If an enabled proc-
ess turns to be disabled or a disabled process turns to be
enabled at time t, the process is said to be switched at time
t. If a discrete process p is triggered at time t, we say that
the discrete process can be fired at time t + d(p)(M(t)). If a
generic process p is triggered at time t, we say that the
generic process can be fired at time t + α.
For an entity e ∈ E and time t, let Sd(t) be the set of discrete
processes which can be fired at time t, and let Ud(t) be the
set of discrete processes which are triggered at time t. For
a discrete process p that can be fired at time t, we denote
by q(p, t) the time when p is triggered. Let Sc(t) be the set
of continuous processes which are enabled at time t. Let
Sg(t) be the set of generic processes which can be fired at
time t.
Note that we can choose a sufficiently small εt > 0 such
that in the interval [t - εt, t), neither discrete nor generic
process is triggered or can be fired and no continuous
process is switched.
Also note the following facts:
1. Sc(t - εt) = Sc(t') for any t' ∈ [t - εt, t) since no contin-
uous process is switched in the interval [t - εt, t).
2. (t') is constant on E - Econtinuous in the interval [t -
εt, t) since neither discrete nor generic process is trig-
gered or can be fired in the interval [t - εt, t), where Econ-
tinuous = {e ∈ E |e is continuous}.
3. For any continuous connector c, u(c)( (t')) is con-
tinuous on [t - εt, t) since by definition u(c) is contin-
uous for Econtinuous  and (t') is constant on E  -
Econtinuous in the interval [t - εt, t).
Then M(t) is defined by the following procedure:
1. Tmp ← M(t - εt), Tmpr ← Mr(t - εt)
2. if t = αk for some integer k ≥ 1 then
for each generic process p ∈ Sg(t)
Tmp' ← Tmp
for each (e, p) ∈ EP with a(e, p) = process
Tmp'(e) ← u(e, p)(Tmp)
for each (p, e) ∈ PE
Tmp'(e) ← u(p, e)(Tmp)
Tmp ← Tmp'
3. for each continuous process p ∈ Sc(t - εt)
Tmp' ← Tmp
for each (e, p) ∈ EP with a(e, p) = process
for each (p, e) ∈ PE
Tmp ← Tmp'
4. for each discrete process p ∈ Sd(t)
Tmp' ← Tmp
for each (e, p) ∈ EP with a(e, p) = process
% M
% M
% M
% M
% M
% M
% M
% M
% M
Tmp e Tmp e u e p M x dx
t
t
t
′ ← ′ −
− ∫ () () (,) ( () ) %
e
Tmp e Tmp e u p e M x dx
t
t
t
′ ← ′ +
− ∫ () () (,) ( () ) %
eBMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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Tmp'(e) ← Tmp'(e) - u(e, p)( (q(p, t)))
for each (p, e) ∈ PE
Tmp'(e) ← Tmp'(e) + u(p, e)( (q(p, t)))
Tmp ← Tmp'
5. M(t) ← Tmp
Then Mr(t) is defined as follows:
6. for each entity e with h(e) = discrete or continuous
7. Mr(t) ← Tmpr.
We call M(t) (t ≥ 0) the behavior of H starting at the initial
marking M(0) = I.   
In the next section, we will introduce the biological back-
ground and explain the modeling method of C. elegans
vulval development mechanisms.
Biological background and modeling of C. elegans vulval 
development
Biological background of C. elegans vulval development
The C. elegans vulva is an egg-laying organ which is consti-
tuted by the descendants of three VPCs. The three VPCs
are the members of six initially equivalent VPCs that are
consecutively numbered P3.p – P8.p (termed Pn.p cells).
In response to extracellular signaling pathways, each VPC
has a potential to adopt one of three alternative cell fates
(1°, 2°, 3°) (see Figure 3(a)). Six cell fates of Pn.p cells
comprise a cell fate pattern in the form of [P3.p P4.p P5.p
P6.p P7.p P8.p]. In wild-type worms, P3.p – P8.p always
adopt a same pattern of fates (i.e., [332123]). The sublin-
eage is then generated according to each specified VPC
fate. The sublineage is a determined pattern of cell divi-
sions which produces a characteristic set of progeny cell
types. Figure 3(b) shows the sublineage of respective VPC
fate according to the criteria defined by Sternberg and
Horvitz [32].
In wild-type C. elegans, an inductive signal LIN-3, an EGF-
like signal produced by gonad, activates the EGFR
homolog LET-23 and a canonical Ras/MAPK cascade in
P6.p adopting the 1° fate. In response to the inductive sig-
nal, P6.p produces LIN-12-mediated lateral signals (LS for
short) that counteract the inductive signal from AC in two
neighboring VPCs, which causes two VPCs to adopt the 2°
fate. In other words, LS induces the expression of negative
regulators (collectively termed lateral signal target (lst)
genes [34]) against the EGF/Ras/MAPK pathway. LS is
encoded by three functionally redundant members of the
Delta/Serrate protein family (dsl-1, apx-1, and lag-2) and
transduced by the LIN-12/Notch receptor. Each lst gene
contains a cluster of binding site LBSs for LAG-1 that is a
DNA binding protein forming a complex with the LIN-12
intracellular domain to activate the transcription of the
target genes [34-36]. Furthermore, two functionally
redundant synthetic Multivulva (synMuv) genes transcrip-
tionally repress the target gene of lin-3 in the hypodermis,
i.e., synMuv genes prevent the surrounding hypodermal
syncytium hyp7 from generating inductive LIN-3 signals
[37]. Without the activation of either inductive or lateral
signaling pathways, P3.p, P4.p, and P8.p adopt the 3° fate
[35]. Thus, the fates of 1°, 2°, and 3° are the productions
of the coordination regulated by three signaling pathways,
i.e., AC induced signaling pathways, the lateral signaling
pathways, and the signaling pathways induced from hyp7
[32,35,38-41]. Figure 4 illustrates the biological diagram
for the multiple signaling events underlying the VPC fate
specification.
Modeling VPC fate specification mechanisms with HFPNe based on 
literature
Figure 5 exhibits a whole HFPNe based VPC fate model
that is constructed by compiling and interpreting the
information appeared in the literature concerning the
VPC fate specification mechanisms [9,32,34-38,42-46].
The whole VPC fate model totally includes 427 entities,
554 processes and 780 connectors. The elements of
HFPNe are changed to biological icons in Cell Illustrator
(on the right side of Figure 2). The icons have been
defined with one of the biological ontology information,
called Cell System Ontology [47]. Although these changes
have no effect on mathematical meaning, it is helpful for
biologists to understand the pathways.
Since six VPCs are initially equivalent, we hereafter
explain modeling operations by using a single VPC fate
model as shown in Figure 6 whose six copies are embed-
ded in the whole VPC fate model in Figure 5. In Figure 6,
24 events directly attending VPC fate specification are
assigned to the processes pi ∈ {p1, • , p24} (see Table 2). A
set of sink processes   denotes the natu-
ral degradation of the substances, whereas a set of source
processes   denotes the translation reac-
tions of initial entities. The left 13 processes {p25, p26, • ,
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Schematic representations of VPC fate specification in wild-type hermaphrodites Figure 3
Schematic representations of VPC fate specification in wild-type hermaphrodites. (a) The anchor cell produces a 
graded inductive signal and causes six equivalent cells to adopt fates in a precise pattern. (b) The sublineage is generated 
according to each specified cell fate. The sublineage is a determined pattern of cell divisions which produces a characteristic set 
of progeny cell types. Sternberg and Horvitz have defined vulval cell types (after two rounds of VPC divisions) by two criteria 
as follows: the axis of the third round nuclear divisions (L, longitudinal axis; T, transverse axis; N, no division; S is to join the 
large hypodermal syncytium (hyp7)), and adherence to the ventral cuticle [32].
Anchor Cell
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p37} are generic processes, which contribute to play the
roles of extracellular stimuli ({p25}) and the cell fate
specification ({p26, p27, • , p37}). Variable mx ∈ {m1, • ,
m32} denotes the concentration of corresponding sub-
stance (see Table 3).
The modeling operation starts from the source process
 denoting an activity that the substance takes part in
the reaction. Here we only explain the case of Ras/MAPK
inductive signaling pathway: LIN-3 ligands and corre-
sponding receptors LET-23 are assigned to the entities
(m1 and m2) connected from the source processes (
and  ), respectively. Next, the ligand-receptor binding
reaction where two entities (m1 and m2) merge into an
entity m3 denoting ligand-receptor complex is repre-
sented via the process p3. Since two ligand-receptor com- ps1
ps1
ps2
Biological diagram for the multiple signaling events underlying VPC specification Figure 4
Biological diagram for the multiple signaling events underlying VPC specification. Biological diagram for the multi-
ple regulatory signaling pathways underlying VPC fate specification. Three VPCs (they can be P6.p, P7.p and P8.p, or P6.p, P5.p 
and P4.p) according to the relative distance to the AC are selected to depict the signaling crosstalk. In the rightmost cell, the 
EGF/MAPK pathway cannot be activated because the induced signal (indicated by a grey line) received by LET-23, is lower than 
the threshold for induction, and the VPC hence adopts the 3° fate. The induction signal with high concentration (indicated by a 
heavy black line) activates the EGF/MAPK pathway and causes the 1° fate. It also has been known that two transcription fac-
tors, LIN-31 and LIN-1 are likely to be the downregulation targets of the MAPK pathway [42]. Both LIN-31 and LIN-1 can be 
phosphorylated by MAPK kinase MPK-1. LIN-31 and LIN-1 usually form a complex that is disrupted by the phosphorylation of 
LIN-31, and LIN-1 dissociates from LIN-31 to let LIN-31 play a role in the proper specification of VPCs. On the other hands, 
ligands for LIN-12 are members of the "DSL" family, an acronym derived from canonical ligands from Drosophila (Delta, Serrate) 
and C. elegans (LAG-2). Binding of DSL ligands to LIN-12/Notch leads to the shedding of the LIN-12/Notch ectodomain (extra-
cellular domain) via cleavage. The remaining transmembrane protein is cleaved constitutively, and the intracellular domain 
translocates to the nucleus, binding to the LAG-1 that usually exists as a transcription factor to repress lst genes. With the 
binding to LAG-1, lst genes expresses LST proteins to counteract the operations of EGF/MAPK pathways by inhibiting VPCs 
from becoming the 1° fate. For the details of LIN-12/Notch signaling in C. elegans, the readers are suggested to refer to [34].
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plexes shape a dimer, the process p4 is used to represent
the homodimerization connecting from the input entity
m3 as well as connecting to the output entity m4 of LIN-
3/LET-23 dimer. Note that the stoichiometry of the input
connector of p4 is set to 2 due to the dimerization. The
dimer is autophosphorylated subsequently which is mod-
eled by using a phosphorylation process p5 connecting
from and to the entities of m4 and m5, respectively. Suc-
cedent reactions for the products of the canonical cas-
cades: active SEM-5 (m7), LET-60 (m9), and MPK-1
(m11) are modeled in the same way using the processes
of activation (p6, p7 and p8). Activated MPK-1 then
moves from the cytoplasm to the nucleus. This movement
is modeled as a translocation reaction by p9.
Based on the understanding of the literature and the
hypothesis reported in [9], we first model downstream
regulation of Ras/MAPK cascades and succedent intracel-
lular reactions induced by LIN-12/Notch signaling
according to newly published literature. The details of the
new biological facts are described in the caption of Figure
4. The new facts concerning the mechanisms of the down-
stream regulation of Ras/MAPK cascades are modeled as
follows: The phosphorylation by m12 further disrupts the
formation of LIN-31/LIN-1 complex (m13) which applies
the process of phosphorylation (p13). The processes p14
and p15 are used to model the transcription of target genes
and the translation of mRNA (m16) regulated by LIN-31
(m31) that acts as a transcriptional activator promoting the
1° fate as a fate candidate (m18).
Two biological fate determination rules applied to VPC 
fate model
When determining cell fates from biological points of
view, several biological fate determination rules can be
taken into account. One major biological fate determina-
tion rule (Rule II) based on temporal order has been
applied to a qualitative model by Fisher et al. [9]. The
approach is based on a discrete model. However, the other
rules such as temporal interval based one (Rule I) cannot
be handled in the same discrete model. This is because the
model cannot deal with the quantitative properties (e.g.,
continuous feature) that are also important to biological
processes, such as the concentration of proteins and reac-
tion rates. With inspiring by this limitation of qualitative
models, we employ these two major biological fate deter-
mination rules – Rule I and Rule II – to VPC fate model.
The model has both discrete and continuous features.
Two fate determination rules are as follows: (i) For Rule I,
the fate will be determined if it satisfies the conditions
that (1) the fate can sustain the behaviors at a certain over-
threshold state within a given length of time, and (2) the
time epoch of the certain over-threshold in (1) is earlier
than the other fate candidate. Figure 7 shows a schema-
tized diagram of a simulation result. In Figure 7, the cell
fate is determined to the 2° fate by using Rule I. The time
course expression of 1° is maintained at the over-thresh-
old state during interval_1, and that of 2° is maintained at
the over-threshold state during interval_2. Although the
time course expression of 1° has two over-threshold
states, only the second interval interval_1 is longer than
the given interval. Thus, the time epoch labeled with "τi of
Rule I" is regarded as the initial time epoch inducing the
second over-threshold state. The VPC adopts the 2° fate
due to τj <"τi of Rule I".
(ii) For Rule II, the cell fate will be priorly adopted accord-
ing to the temporal sequence of the first time epoch
inducing over-threshold state. In Figure 7, we can observe
that the first time epoch (i.e., "τi of Rule II") inducing
The whole HFPNe based VPC fate model underlying the fate specification mechanisms involving six equivalent VPCs Figure 5
The whole HFPNe based VPC fate model underlying the fate specification mechanisms involving six equiva-
lent VPCs.
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Table 2: Biological interpretation based on literature and assignment of each process in Figure 6
Wet experiments results published in literature #1 #2 Reaction type Refs
Translocation of LIN-3 emanated from AC to P5.p and P7.p p1 LSMass(m1*0.1*low, 0.1) Translocation [9,35]
Translocation of LIN-3 emanated from AC to P3.p, P4.p and P8.p p2 LSMass(m1*0.1*mid, 0.1) Translocation [9,35]
ligands LIN-3 binding to LET-23 to form a ligand-receptor complex p3 LSMass(m1*0.1*high, 0.1) Binding [43,44]
Two identical LIN-3 LET-23 complex combining to form a dimer p4 LSMass(m3*0.1, 0.5) Dimerization [43,44]
Autophosphorylation following the dimerization of ligand-receptor complex p5 LSMass(m4*0.1, 0.5) Autophosphorylation [43,44]
SEM-5 is activated by LIN-3 LET-23 dimer p6 LSMass(m5*m6*0.1, 0.5) Enzymic reaction [9,35]
LET-60 is activated by upstream SEM-5 p7 LSMass(m7*m8*0.1, 0.5) Enzymic reaction [9,35]
Inactive MPK-1 is activated by upstream LET-60 p8 LSMass(m9*m10*0.1, 0.5) Enzymic reaction [9,35]
The movement of MPK-1 from cytoplasm to nucleus p9 LSMass(m11*0.1, 0.5) Translocation -
Active MPK-1(N) downregulates the target genes of lst and transcribes the 
mRNA of lateral signal (LS)
p1
0
LSMass(m12*0.1, 0.5) Transcription [9]
LS mRNA is translated to LS molecules p1
1
LSMass(m17*0.1, 0.5) Translation -
Translated LS molecules are released to combine with p1
2
LSMass(m19*0.1, 0.5) Translocation [34]
LIN-12 receptors
LIN-31/LIN-1 complex is dissociated to individual active p1
3
LSMass(m12*m13*0.1, 0.5) Phosphorylation [38,45]
LIN-31 and LIN-1 by the phosphorylation of active MPK-1
Active a MPK-1(N) acts as transcription factor to tran- p1
4
LSMass(m14*0.1, 0.5) Transcription [42]
scribe vulval genes to mRNA
mRNA of vulval genes is translated and cause the 1 p1
5
LSMass(m16*0.1, 0.5) Translation [42]
cell fate
LIN-12 receptor received the LS molecules from the ad- p1
6
LSMass(m20*mκ*1.0, 0.1) Binding [32,34]
jacent Pn.p and shape a ligand-receptor complex
LIN-12 receptor received the LS molecules from its own p1
7
LSMass(m20*mκ*1.0, 0.1) Binding [32,34]
Pn.p and shape a ligand-receptor complex
LIN-12 receptor received the LS molecules from the ad- p1
8
LSMass(m20*mκ*0.1, 0.1) Binding [32,34]
jacent Pn.p and shape a ligand-receptor complex
Binding of LS ligands to LIN-12/Notch receptor leads to p1
9
LSMass(m21*0.1, 0.5) Shedding/Cleavage [34]
shedding of the LIN-12/Notch extracellular domain via cleavage
Cleaved intracellular domain of LIN-12/Notch receptor move from cytoplasm 
to nucleus
p2
0
LSMass(m23*0.1, 0.5) Translocation [34,46]
Cleaved LIN-12/Notch receptor promote the target lst genes transcribed into 
mRNA of lst genes
p2
1
LSMass(m24*0.1, 0.5) Transcription [34,36]
LST mRNA is translated to LST in cytoplasm p2
2
LSMass(m26*0.1, 0.5) Translation -
LIN-12 immediately induces lst expression thus prevents cells from engaging the 
mechanisms reducing LIN-12 activity
p2
3
LSMass(m20*lin12_init, 0.1) Production [9]
LIN-3 emanating from hyp7 binds to LET-23 to form a complex p2
4
LSMass(m2*m28*0.1, 0.5) Expression [9,37]
Table 2: The column of #1 represents corresponding processes in the HFPNe model. Twenty-four events are assigned to the processes pi ∈ {p1, • , 
p24}. Each reaction speed of the processes is assigned as shown in the column of #2, in which several reaction speeds have been tuned manually. 
Reaction types of the processes are described in the fourth column with the literature facts given in the fifth column. Variable mx ∈ {m1, • , m32} 
denotes the concentration of corresponding substance (see Table 3). The variable mk is used to collectively denote the concentration of the LS 
molecules generated from the adjacent Pn.p. The values of high, mid, and low are assigned to 100, 1, and 0.01. For example, the process p9 has a 
reaction speed with a noise denoted by LSMass(m11 *0.1, 0.5), i.e., the reaction speed depends on the concentration of MPK-1{active} (C) in the 
cytoplasm (m11). LSMass() is a function of log-normal distribution (see text).BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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over-threshold state of 1° is earlier than 2°, and therefore
the 1° fate will be adopted by Rule II no matter how long
the over-threshold state of 1° will continue. Preliminary
notations and mathematical definitions of two rules are
given in the Additional file 1.
In Figure 6, two dashed-line ellipses illustrate the topolog-
ical connections representing Rule I (blue ellipse) and
Rule II (red ellipse) which jointly use the values of m18
and m30 as the inputs for the fate specification. Variables
m18 (denoting the concentration of 1°) and m30 (denoting
the concentration of 2°) are regarded as two cell fate can-
didates for determining final VPC fate. Two rules are
implemented with a script-based language Pnuts in Cell
Illustrator [48]. The detailed properties and descriptions
of the entities concerning the fate specification are sum-
marized in Table 4. The activity functions of related proc-
esses and update functions of the connectors are
summarized in Tables 5 and 6.
Further, several variables are designed to reserve alterable
values according to different genotypes (see Table 7). Fig-
ure 8 shows a Genotype Configuration panel and a struc-
ture of auto-switching mechanism. The Genotype
Configuration panel includes an AC and four mutant var-
iables. AC, lin15, vul and lst can toggle between true and
false. lin12 has three string-type values, i.e., "wt", "ko",
"gf", indicating three genetic conditions of wild, knockout
and overexpression of lin-12.
It is obvious that the combination number is 48 as listed
in Table 8. Forty-eight genotypes have the features as fol-
lows:
(i) For 15 genotypes whose RowID are indicated by
boldface and labeled with square brackets, the fate
patterns of each genotype have the in vivo experimen-
tal data reported in [32] (refer to the column of "Fate
Patterns (ST)" in Tables 8 and 9).
(ii) For eight genotypes whose RowID are indicated
with the superscript (†), the fate patterns of each gen-
otype have been confirmed by model checking
approach in the discrete model in [9], which are also
consistent with the biological facts [35,46,49-53].
(iii) For the left 25 genotypes, the patterns of each gen-
otype have only been verified in [9], because these
genotypes are usually experimentally intractable. The
reason is that, the population of double, triple or
quadruple mutants might be technically difficult to be
generated [9].
(iv) For four genotypes (i.e., RowID 5, 21, 29, and 45)
are called unstable patterns, because genetic condition
will lead to an unstable fate pattern as shown in Table
9.
In the next subsection, we will execute simulation to
investigate the characteristics of predicted fate patterns of
48 genotypes, in particular, four genotypes leading to the
unstable fate pattern, and to evaluate two rules employed
to the VPC fate model by comparing with three simula-
tion targets (i.e., JA, ST, and STA) as shown in Figure 1(b).
Simulation-based model checking approach of 
determining VPC specification by using Cell Illustrator
We first demonstrate how to assign parameters to the VPC
fate model. Then, we consider three simulation targets to
investigate the properties of fate patterns, and to evaluate
two proposed rules. Finally, a large number of simula-
tions are performed with the use of "High-Speed Simula-
Table 3: Entities in the HFPNe model of Figure 6
Entity Name Variable (mx)
LIN-3(AC) m1
LET-23 m2
LIN-3/LET-23 complex m3
LIN-3/LET-23 dimer m4
LIN-3/LET-23 dimer{p} m5
SEM-5 m6
SEM-5{active} m7
LET-60 m8
LET-60{active} m9
MPK-1 m10
MPK-1{active}(C) m11
MPK-1{active}(N) m12
LIN-1/LIN-31 complex m13
LIN-31{active} m14
LIN-1{active} m15
Vulval gene mRNA m16
LS mRNA m17
1° cell fate m18
LS molecules(C) m19
LIN-12/Notch receptor m20
LIN-12R/LS complex m21
Cleaved fraction of LIN-12R/LS (extracellular domain) m22
Intracellular domain of LIN-12/LS complex (C) m23
Intracellular domain of LIN-12/LS complex (N) m24
LAG-1 m25
LST mRNA m26
LST inhibitors m27
LIN-3 emanating from hyp7 m28
LIN-15 in hyp7 m29
2° cell fate m30
Final fate determined by Rule II m31
Final fate determined by Rule I m32
Table 3: Variable mx ∈ {m1, • , m32} indicates the concentration of each 
substance that actually takes part in the biological reactions. Initial 
value represents the initial content of an entity.BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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HFPNe model of a single VPC in Figure 5 Figure 6
HFPNe model of a single VPC in Figure 5. The naming rules of the VPC fate model are defined as follows: (i) each 
"entity" is labeled with the name of a substance (e.g. LIN-3, LET-60, and lst gene), (ii) the name of a complex consisting of two 
or more protein components A1, A2, • , AM (M ∈ Z+) is represented as A1 _A2_ •  _AM, and (iii) an additional label (C) or (N) is 
attached at the end of a substance name, when it happens to distinguish the location of the substance in the cytoplasm or the 
nucleus. The label of {active} denotes the active state of the enzyme, and {p} denotes that the substance is phosphorylated.
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tion Module" of Cell Illustrator. The simulation results are
given in the form of fitting score and variation frequency of
each pattern of 48 genotypes. The fitting score is a percent-
age of the total numbers of predicted patterns appeared in
each genotype); the variation frequency is the number of
each appearing fate pattern in the respective genotype dur-
ing the simulation experiments.
Parameter assignment
The VPC fate model in Figure 5 reflects the interrelation of
each substance. All parameters for the reaction rates of
processes and the steady state of the substance are tuned
manually with repeating simulation until concentration
behaviors of proteins correspond to the biological facts.
Note that it is hard to decide optimal values of these
parameters, since data from biological experiments are
very insufficient to determine them.
We thus simplify the kinetic parameters to the same
speeds mx*0.1 with noise for the process pi∈ {p1, p2, • ,
p24} (see Table 2); the speed of the source process
 is assigned to 1.0 denoting the pro-
duction rate of substance. When constructing the quanti-
tative VPC fate model, threshold values (partly shown in
Figure 8 and Table 10) of each reaction are assigned as real
number, and the parameters for the steady states of the
substances induced by the stimulations from anchor cell
and hyp7 are carefully tuned by hand. Lots of trial and
error operations have been performed repeatedly until
appropriate parameters for simulation are determined.
The VPC fate model in Figure 5 is available from [54],
which can be executed on Cell Illustrator [24] or Java web
start software Cell Illustrator Online 4.0 (CIO) [25]. All
the parameters have been saved in the csv format, which
are also available online at the same website [54].
Three simulation targets for validation
[Obtaining fate patterns (JA) by using model checker: MOCHA]
Model checking is powerful technique for automatically
verifying the system requirements. The essential idea of
model checking is that, with an exhaustive exploring of all
reachable states and transitions of a modeled system, sys-
tem properties (expressed as a formal specification) are
examined whether the properties are satisfied or not. A
model checker (e.g., MOCHA[55]) accepts the modeled
system and the specification as its inputs. The checker
then outputs yes if the model satisfies the given specifica-
tion and generates a counterexample otherwise. The coun-
terexample indicates why the model does not satisfy the
given specification. By repeating operations of revising the
errors examined by the counterexamples, the modeled
system can be refined to satisfy enough system specifica-
tions [1,2].
Fisher  et al. have firstly applied the model checking
approach for validating biological systems of C. elegans
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A schematized diagram depicting the fate specification methods by using Rule I and Rule II Figure 7
A schematized diagram depicting the fate specification methods by using Rule I and Rule II. "τi of Rule I" repre-
sents the first time epoch that the concentration of 1° (m18) exceeds threshold_1, and the time length interval_starting from "τi 
of Rule I" is longer than or equal to the given interval when using Rule I. "τj of Rule II" represents the first time epoch that the 
concentration of 1° exceeds threshold_1, no matter how long this interval will continue when using Rule II. τi represents the 
first time epoch that the concentration of 2° (m30) exceeds threshold_2. Variables m18 (denoting the concentration of 1°) and 
m30 (denoting the concentration of 1°) are regarded as two cell fate candidates for determining final VPC fate. Pn.p_fate1/
2_record1/2 indicated in the brackets are the entity names used in Cell Illustrator.
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Table 4: Properties of entities for the HFPNe model of Figure 6
Variable Entity name Entity type Value type Initial value Variable description
AC AC Generic Boolean true/false Entity can be switched according to the 
genotype
lin12 lin-12 Generic String "wt"/"ko"/"gf" Entity can be switched according to the 
genotype
lin15 lin-15 Generic Boolean true/false Entity can be switched according to the 
genotype
vul vul Generic Boolean true/false Entity can be switched according to the 
genotype
lst lst Generic Boolean true/false Entity can be switched according to the 
genotype
m31 Pn.p_FinalFateII Continuous Double 0 Final Fate determined by Rule II
m32 Pn.p_FinalFateI Continuous Double 0 Final Fate determined by Rule I
m33 m33 Generic Boolean true An entity designed to judge if m18/m30 
exceeds respective threshold when lin-12 
is "wt"/"ko"
m34 m34 Generic Boolean true An entity for judging if m18/m30 exceeds its 
threshold when lin-12 is "gf"
m35 m35 Generic Boolean false An entity used as a flag to judge if m37 can 
get the time epoch when m18 is over 
threshold_1
m36 m36 Generic Boolean false An entity used as a flag to judge if m38 can 
get the time epoch when m18 is below 
threshold_1
m37 Pn.p_fate1_record1 Continuous Double 0 An entity designed to reserve a time 
epoch that m18 exceeds threshold_1
M38 Pn.p_fate1_record2 Continuous Double 0 An entity designed to reserve a time 
epoch that m18 decreases below 
threshold_1
m39 m39 Generic Boolean false An entity used as a flag to judge if m41 can 
get the time epoch when m30 is over 
threshold_2
m40 m40 Generic Boolean false An entity used as a flag to judge if m42 can 
get the time epoch when m30 is below 
threshold_2
m41 Pn.p_fate2_record1 Continuous Double 0 An entity designed to reserve a time 
epoch that m30 exceeds threshold_2
m42 Pn.p fate2_record2 Continuous Double 0 An entity designed to reserve a time 
epoch that m30 decreases below 
threshold_2
m43 Pn.p_m1_interval Continuous Double 0 Time difference between m38 and m37 that 
is the longest time interval at the present 
time epoch
m44 Pn.p_fate1_init Continuous Double 0 Time epoch that m18 exceeds threshold_1 
to the initial one in the time span of m43 
corresponding
m45 Pn.p_m2_interval Continuous Double 0 Time difference between m42 and m41 that 
is the longest time interval at the present 
time epoch
m46 Pn.p_fate2_init Continuous Double 0 Time epoch that m30 exceeds threshold_2 
corresponding to the initial one in the 
time span of m45
- lin3_init Continuous Double 100 Amount of LIN-3 impulse emanating from 
AC
- Steady_state_time(Gonad) Continuous Double 400 Time epoch of substance that achieve a 
steady state level
simultime Simulation_time Continuous Double 2000- 
getSamplingInterval(simulator)
The length of simulation timeBMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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with biological experiments [9]. They have constructed a
discrete and state-based mechanistic model underlying
the inductive and lateral signaling crosstalk by using the
language of reactive modules [13] and MOCHA. Further,
they have confirmed that the model can reproduce
reported biological behavior observed in 22 genotypes
with MOCHA. However, their method has the following
weaknesses that are desired to be solved in this paper:
(1) The details of predicted fate patterns of four unsta-
ble patterns (RowID 5, 21, 29, and 45) are not explic-
itly given. That is, only summarized patterns are given.
However, it is important to reveal if all the expansions
of predicted (summarized) patterns will appear even
though the predicted patterns satisfy the given specifi-
cation. For example, in the case of ac-; lin-12gf; lin-
15ko double mutants (RowID 45 in Table 8), the pre-
Table 5: Properties of processes for the HFPNe model of Figure 6
Process Process type Process activity
p25 Generic if (IfTime(simulator, steady_state_time(Gonad)) && AC == true)
{return true;} else {return false;}
p26 Generic if ("gf".equals(lin12)) {return false;} else {return true;}
p27 Generic if ("gf".equals(lin12) && (getElapsedTime(simulator) >
simultime+getSamplingInterval(simulator)))
{return true;} else {return false;}
p28 Generic if ((m35 == true && m36 == true) && m18 > = threshold_1)
{return true;} else {return false;}
p29 Generic if (m18 > = threshold_1 && m35 == false) {return true;}
else {return false;}
p30 Generic if ((m35 == true && m36 == false && m18 < threshold_1) ||
(m35 == true && m36 == false && m18 > = threshold_1 &&
IfTime(simulator, simultime))) {return true;} else {return false;}
p31 Generic if (((m39 == true) && (m40 == true)) && (m30 > = threshold_2))
{return true;} else {return false;}
p32 Generic if ((m30 > = threshold_2) && (m39 == false)) {return true;} else {return false;}
p33 Generic if ((m39 == true && m40 == false && m30 < threshold_2) ||
(m39 == true && m40 == false && m30 > = threshold_2 &&
IfTime(simulator, simultime))) {return true;} else {return false;}
p34 Generic if ((m35 == true && m36 == true) || (m35 == true &&
getElapsedTime(simulator)>simultime)) {return true;} else
{return false;}
p35 Generic if ((m39 == true && m40 == true) || (m39 == true &&
getElapsedTime(simulator)>simultime)) {return true;} else
{return false;}
p36 Generic if (getElapsedTime(simulator)
> simultime+getSamplingInterval(simulator) &&
("gf".equals(lin12) == false)) {return true;} else {return false;}
p37 Generic if ((getElapsedTime(simulator)
> simultime + getSamplingInterval(simulator)) &&
"gf".equals(lin12)) {return true;} else {return false;}
Table 5: External Java functions getElapsedTime(simulator), getSamplingInterval(simulator), and IfTime(simulator, time) return the value of elapsed 
time during simulation, the sampling interval of simulator, and true/false by judging if elapsed time equals to the value of time, respectively. All the 
functions are written in Pnuts language [48].BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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Table 6: Update functions of connectors for HFPNe model of Figure 6
Connector Name Connector type Update function
Rule I:
if ("gf" .equals(lin12)) == false holds, the connectors are updated as follows:
c14(p28, m35) process return false;
c15(p28, m36) process return false;
c16(m35, p29) process return true;
c17(m36, p30) process return true;
c18(p29, m37) process return getElapsedTime(simulator);
c19(p30, m38) process return getElapsedTime(simulator);
c20(p31, m39) process return false;
c21(p31, m40) process return false;
c22(m39, p32) process return true;
c23(m40, p33) process return true;
c24(p32, m41) process return getElapsedTime(simulator);
c25(p33, m42) process return getElapsedTime(simulator);
c26(p34, m43) process if (m43! = 0 && m43 < m38-m37) {return m38-m37;}
else if (m43! = 0 && P3p_m1_interval > = m38-m37)
{return m43;} else {return m38-m37;}
c27(p34, m44) process if (m44! = 0 && m43 < m38-m37) {return m37;}
else if (m44! = 0 && m43 > = m38-m37)
{return m44;} else {return m37;}
c28(p35, m45) process if (m45! = 0 && m45 < m42-m41) {return m42-m41;}
else if (m45! = 0 && m45 > = m42-m41)
{return m45;} else {return m42-m41;}
c29(p35, m46) process if (m46! = 0 && m45 < m42-m41) {return m41;}
else if (m46! = 0 && m45 > = m42-m41)
{return m46;} else {return m41;}
c30(p36, m32) process if (m43 > = interval && m45 > = interval) {if (m44 < = m46) {return 1;} else {return 2;}}
else if (m43 > = interval && m45 < interval) {return 1;}
else if (m43 < interval && m45 > = interval)
{return 2;} else{return 3;}
c31(p37, m32) process if (m43 > = interval && m45 > = interval) {return 1;}
else if (m43 > = interval && m45 < interval) {return 1;}
else if (m43 < interval && m45 > = interval)
{return 2;} else {return 3;}
c32(p25, m1) process lin3_init
Rule II:
if ("gf" .equals(lin12)) == false holds, the connectors are updated as follows:BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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dicted pattern is [1/2, 1/2, 1/2, 1/2, 1/2, 1/2 ] in [9]. It
is obvious that the pattern includes totally 26 = 64 pos-
sible fate patterns, but it is still ambiguous if all these
64 patterns will be adopted in in vivo experiments.
(2) The distribution and variation of individual
behavior of predicted fate patterns are not sufficient to
understand the features of the fate patterns. In other
words, it is necessary to clarify the occurrence proba-
bility (called variation frequency) of each predicted pat-
tern, which is considered to facilitate obtaining an
overall distribution of the predicted fate patterns,
especially, the four unstable patterns.
To improve the first weakness, we introduce a new proce-
dure GENERATENECESSARYFATEPATTERNS by repeating the
use of "counterexample" to obtain necessary fate patterns
on MOCHA.
«PROCEDURE GENERATENECESSARYFATEPATTERNS»
[******]: A state pattern of six VPC fates; * is one of three
alternative fates (1°, 2°, and 3°); i.e., [111111] denotes a
c6(m33, p26) process if (m18 > = threshold_1 || m30 > = threshold_2)
{return false;} else {return true;}
c7(m18, p26) process return m18;
c8(m30, p26) process return m30;
c9(p26, m31) process if(m33 == true) {if(m18 > = threshold_1)
{return 1;} else if (m30 > = threshold_2)
{return 2;} else {return 3;}} else {return m31;}
if ("gf" .equals(lin12)) == true holds, the connectors are updated as follows:
c10(m18, p27) process return m18;
c11(m34, p27) process if (m18 > = threshold_1 && m30 > = threshold_2)
{return false;} else {return true;}
c12(m30, p27) process return m30;
c13(p27, m31) process if(m18 < threshold_1 && m30 < threshold_2)
{return 3;} else if(m285 > = threshold_1)
{return 1;} else {return 2;}
Table 6: Update functions of connectors for HFPNe model of Figure 6 (Continued)
Table 7: Detailed parameters and functions of Figure 8.
Variable name Update function
ci(P1, threshold_1) if ("gf".equals(lin12)) {return lin12gf_threshold_1;} else
{return normal_threshold_1;}
cj(P1, threshold_2) if ("gf".equals(lin12)) {return lin12gf_threshold_2;} else
{return normal_threshold_2;}
ck(P2, interval) if ("gf".equals(lin12)) {return lin12gf_interval;}
else
{return normal_interval;}
cp(P3, lin12_init) if ("gf".equals(lin12)) {return LSMass(2.0,1.0);}
else if ("ko".equals(lin12)) {return 0;}
else {return LSMass(1.0,1.0);}
Table 7: The auto-switching mechanism of determining the value of threshold_1, threshold_2, interval and expression speed of lin12 under different 
mutant combinations as shown in the block of "Genotype Configuration" of Figure 8. If lin12 equals to "wt", a generic process P3 will fire to deposit 
LSMass(1.0,1.0) as an expression speed of lin-12; if lin12 equals to "ko", P3 will deposit 0; and if lin12 equals to "gf", P3 will fire to deposit 
LSMass(2.0,1.0) as the speed denoting an overexpression of lin-12. The variables of threshold_1, threshold_2 and interval are designed likewise. All 
update functions are written in Pnuts language [48]BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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fate pattern with 1° for all VPCs. In total, there are 729(=
36) fate patterns.
RS: A set to store intermediate fate patterns required for a
genotype.
Verify: A MOCHA procedure to verify if the predication
holds for the model. The input is the RS. If there is no
counterexample for the RS, ϕ will be returned. If the coun-
terexample is generated for the RS, one of the counterex-
amples will be returned at random.
The new procedure to derive whole fate patterns for a gen-
otype is as follows: 1. RS ← {[111111]}
2. do c ← Verify(RS)
3. RS ← RS ∪ {c}
4. while c ≠ ϕ
5. c ← Verify(RS\{[111111]})
6. if c = ϕ
7.  return RS\{[111111]}
8. else
The panel of Genotype Configuration and the automatic-switching mechanisms to determine the values of threshold_1/ threshold_2, interval, and lin12_init according to the different genetic conditions Figure 8
The panel of Genotype Configuration and the automatic-switching mechanisms to determine the values of 
threshold_1/threshold_2, interval, and lin12_init according to the different genetic conditions.
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Table 8: Summary of the VPC fate patterns of 48 combinations concerning the AC and four mutants.
RowI
D
AC Genotype Fate Patterns (JA) Fate Patterns (ST) Fate Patterns (STA) Ref.
lin-12 lin-15 vul lst 
P3.pP4.pP5.pP6.pP7.pP8.p
P3.pP4.pP5.pP6.pP7.pP8.p P3.pP4.pP5.pP6.pP7.pP8.p
1† + wt wt wt wt [332123] - - [49]
2† + wt wt wt ko [331113] - - [35,50]
[3] + wt wt ko wt [333333] [333333] [331113] [331123] [331133]
[332313] [332323] [332333]
[333323] [333333]
[32]
4† + wt wt ko ko [333333] - - u.d.
[5] + wt ko wt wt Unstable pattern 
(refer to Table 9)
[32]
6† + wt ko wt ko [111111] - - [46]
[7] + wt ko ko wt [333333] [333333] [333333] [32,37,51
]
8 + wt ko ko ko [333333] - - n.d.
[9] + ko wt wt wt [331113] [331113] [311111] [311112] [311113]
[321111] [321112] [321113]
[331111] [331112] [331113]
-
[32]
10† + ko wt wt ko [331113] - - u.d.
[11] + ko wt ko wt [333333] [333333] [311113] [311123] [311133]
[331133] [331213] [331223]
[332133] [332213] [332223]
[333133] [333213] [333223]
-
[32]
12 + ko wt ko ko [333333] - - n.d.
[13] + ko ko wt wt [111111] [111111] [111111] [32]
14 + ko ko wt ko [111111] - - n.d.
15 + ko ko ko wt [333333] - - n.d.
16 + ko ko ko ko [333333] - - n.d.
[17] + gf wt wt wt [222122] [222122] [122122] [222122] [322122] [32]
18 + gf wt wt ko [221112] - - n.d.
[19] + gf wt ko wt [222222] [222222] [122222] [222222] [322222] [32]
20 + gf wt ko ko [222222] - - n.d.
[21] + gf ko wt wt Unstable pattern 
(refer to Table 9)
[32]BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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22 + gf ko wt ko [111111] - - n.d.
23 + gf ko ko wt [222222] - - n.d.
24 + gf ko ko ko [222222] - - n.d.
25† - wt wt wt wt [333333] - - [52]
26† - wt wt wt ko [333333] - - [50]
27 - wt wt ko wt [333333] - - n.d.
28 - wt wt ko ko [333333] - - n.d.
[29] - wt ko wt wt Unstable pattern 
(refer to Table 9)
[32]
30 - wt ko wt ko [111111] - - n.d.
31 - wt ko ko wt [333333] - - n.d.
32 - wt ko ko ko [333333] - - n.d.
[33] - ko wt wt wt [333333] [333333] [333333] [32]
34 - ko wt wt ko [333333] - - n.d.
35 - ko wt ko wt [333333] - - n.d.
36 - ko wt ko ko [333333] - - n.d.
[37] - ko ko wt wt [111111] [111111] [111111] [111121] [111131] [32]
38 - ko ko wt ko [111111] - - n.d.
39 - ko ko ko wt [333333] - - n.d.
40 - ko ko ko ko [333333] - - n.d.
[41] - gf wt wt wt [222222] [222222] [122222] [222222] [322222] [32]
42† - gf wt wt ko [222222] - - [50]
[43] - gf wt ko wt [222222] [222222] [222222] [32,53]
44 - gf wt ko ko [222222] - - n.d.
[45] - gf ko wt wt Unstable pattern 
(refer to Table 9)
[32]
46 - gf ko wt ko [111111] - - n.d.
47 - gf ko ko wt [222222] - - n.d.
48 - gf ko ko ko [222222] - - n.d.
Table 8: n.d.: not determined, i.e., the fate pattern is only predicted by the in silico model without in vivo evidences to support. In lstko mutant, all lst 
genes are null: ark-1, lip-1, dpy-23, lst-1, lst-2, lst-3, and lst-4. In vulko mutant, the genes of let-23, sem-5, let-60, mpk-1 are null. u.d.: unpublished data; 
AC(+/-): anchor cell formed/ablated; 1: 1°; 2: 2°; 3: 3°.
Table 8: Summary of the VPC fate patterns of 48 combinations concerning the AC and four mutants. (Continued)BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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Table 9: Expanded results of four unstable VPC patterns with respect to the results of [9] and [32]
RowID [5] RowID [21]
Predicted patterns Predicted patterns
Fate Patterns (JA) Fate Patterns (ST) Fate Patterns 
(STA)
Fate Patterns (JA) Fate Patterns (ST) Fate Patterns 
(STA)
[1/2,1/2,2,1,2,1/2]
(Total fate number: 8)
[1/2,1/2,2,1,2,1/2] [1/2,1/2,2,1,2,1/2]
+a
[1/2,1/2,2,1,2,1/2]
(Total fate number: 8)
[2,1/2,2,1,2,1/2] [2,1/2,2,1,2,1/2]
+a
[112121] [122121]
[212121]
[112121] [112122]
[122121] [122122]
[212121] [212122]
[222121] [222122]
[112121] [112122]
[112123] [122121]
[122122] [212121]
[212122] [212123]
[222121] [222122]
[312121] [312122]
[312123]
[112121] [122121]
[212121]
[212121] [212122]
[222121] [222122]
[212121] [212122]
[222121] [222122]
Total fate number: 3 Total fate number: 3
RowID [29] RowID [45]
Predicted patterns Predicted patterns
Fate Patterns (JA) Fate Patterns (ST) Fate Patterns 
(STA)
Fate Patterns (JA) Fate Patterns (ST) Fate Patterns 
(STA)
[1/2,1/2,1/2,1/2,1/2,1/
2]
[1/2,1/2,1/2,1/2,1/2,1/
2]
[1/2,1/2,1/2,1/2,1/2,1/
2]
[1/2,1/2,1/2,1/2,1/2,1/
2]
[1/2,1/2,1/2,1/2,1/2,1/
2]
[1/2,1/2,1/2,1/2,1/2,1/
2]
(Total fate number: 
64)
+a
(Total fate number: 
64)
+a
[111111] [111112] [111111] [111112] [111111] [111112] [111111] [111112] [111111] [111112] [111111] [111112]
[111121] [111211] [111121] [111122] [111121] [111122] [111121] [111211] [111121] [111122] [111121] [111122]
[111212] [111221] [111211] [111212] [111211] [111212] [111212] [111221] [111211] [111212] [111211] [111212]
[112111] [112112] [111221] [111222] [111221] [111222] [112111] [112112] [111221] [111222] [111221] [111222]
[112121] [112211] [112111] [112112] [112111] [112112] [112121] [112211] [112111] [112112] [112111] [112112]
[112212] [121111] [112121] [112122] [112121] [112122] [112212] [121111] [112121] [112122] [112121] [112122]
[121112] [121121] [112211] [112212] [112211] [112212] [121112] [121121] [112211] [112212] [112211] [112212]
[121211] [121212] [112221] [112222] [112221] [112222] [121211] [121212] [112221] [112222] [112221] [112222]
[121221] [122111] [121111] [121112] [121111] [121112] [121221] [122111] [121111] [121112] [121111] [121112]
[122112] [122121] [121121] [121122] [121121] [121122] [122112] [122121] [121121] [121122] [121121] [121122]
[211111] [211112] [121211] [121212] [121131] [121211] [211111] [211112] [121211] [121212] [121211] [121212]
[211121] [211211] [121221] [121222] [121212] [121221] [211121] [211211] [121221] [121222] [121221] [121222]
[211212] [211221] [122111] [122112] [121222] [122111] [211212] [211221] [122111] [122112] [122111] [122112]
[212111] [212112] [122121] [122122] [122112] [122121] [212111] [212112] [122121] [122122] [122121] [122122]
[212121] [212211] [122211] [122212] [122122] [122211] [212121] [212211] [122211] [122212] [122211] [122212]
[212212] [122221] [122222] [122212] [122221] [212212] [122221] [122222] [122221] [122222]
[211111] [211112] [122222] [211111] [211111] [211112] [211111] [211112]
[211121] [211122] [211112] [211121] [211121] [211122] [211121] [211122]
[211211] [211212] [211122] [211211] [211211] [211212] [211211] [211212]
[211221] [211222] [211212] [211221] [211221] [211222] [211221] [211222]
[212111] [212112] [211222] [212111] [212111] [212112] [212111] [212112]
[212121] [212122] [212112] [212121] [212121] [212122] [212121] [212122]
[212211] [212212] [212122] [212211] [212211] [212212] [212211] [212212]
[212221] [212222] [212212] [212221] [212221] [212222] [212221] [212222]
[221111] [221112] [212222] [221111] [221111] [221112] [221111] [221112]
[221121] [221122] [221112] [221121] [221121] [221122] [221121] [221122]
[221211] [221212] [221122] [221211] [221211] [221212] [221123] [221211]BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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9.  return RS
In the above procedure, step 1 is an initialization of RS.
Steps 2 – 4 are the main part to obtain the fate patterns by
repeating the use of "counterexample". Steps 5 – 9 are
designed to check if the initial fate pattern is necessary or
not. By executing the procedure, the results of required
fate patterns of 48 genotypes are summarized in the
fourth column of Table 8, and the first and fourth col-
umns of Table 9. The predicted fate patterns of each gen-
otype derived by using our procedure are collectively
called Fate Patterns (JA) (JA for short). It is clear that the
number of predicted fate patterns investigated by our
method is far smaller than the one summarized by [9] (see
Table 9). The source code used to obtain JA with MOCHA
can be found at the CSML website [54].
[Fate patterns (ST) obtained from in vivo data]
Sternberg and Horvitz have summarized the VPC fate pat-
terns of 15 genotypes by the observation of anatomy and
the cell lineages in living C. elegans using Nomarski differ-
ential interference contrast optics (see Table 4 in the orig-
inal paper [32]). We list the fate patterns of these 15
genotypes (refer to the fifth column in Table 8, and the
second and fifth columns in Table 9).
[Fate patterns (STA) obtained from in vivo data including hybrid 
lineage observations]
In [32], we have noticed that some biological observa-
tions of cell lineages have not received enough attentions.
These observations are likely difficult to be determined
accurately according to the two criteria defined by Stern-
berg and Horvitz [32,39]. The reason is that some lineages
were not interpretable as 1° or 2° by two criteria, i.e.,
observed lineages may result in possible inaccuracy in the
observations which includes mis-scoring adherence to
ventral cuticle owing to deformations in cuticle as animals
bend, as well as variations in division axes [32]. In some
cases, lineages are hybrid, e.g., [S TT] in which [S] is the
production of the characteristics of the 3° fate, and [TT]
can be the lineage of either the 1° or 2° fate. Sternberg
and Horvitz have suggested that hybrid sublineage is a
result of imprecise decision, and the specification is
allowed to have a number of outcomes. When a system
comes close to a certain threshold, it can be considered
that partial functions are involved to express the results in
the formation of hybrid lineage [39].
Inspired by the observation of hybrid lineage, it seems rea-
sonable to put those uninterpretable experimental data
together with the fate patterns of [32] (i.e., ST) as the sim-
ulation targets for validation. By investigating the experi-
mental results of the vulval cell lineage given in [32], we
explain the cell fate of such an uninterpretable lineage as
three plausible fate candidates: 1°, 2°, and 3° fates. Thus,
the VPC fate pattern including the uninterpretable lineage
is extended to three predicted fate patterns (see STA block
in Figure 1(b)). For example, in the case of vulko (RowID
3 in Table 8), we observed such a cell lineage: [[S S] [S S]
[S S] [S TT] [S S] [S S] ], in which [S S] is a cell lineage of
3° and [S TT] is a hybrid lineage and is interpretable by
neither two criteria defined in [32] nor the method in [9].
This cell lineage is determined by the fate pattern
[333?33]. We thus suppose to interpret this VPC fate pat-
tern to three fate pattern extensions of [333133],
[333233], and [333333], i.e., extend "?" (uncertain fate)
to the 1°, 2°, and 3° fate. All the possible cell fate patterns
including extended fate patterns are shown in the column
[221221] [221222] [221212] [221221] [221221] [221222] [221212] [221221]
[222111] [222112] [221222] [222111] [222111] [222112] [221222] [221223]
[222121] [222122] [222112] [222121] [222121] [222122] [221321] [221322]
[222211] [222212] [222122] [222211] [222211] [222212] [221323] [222111]
[222221] [222222] [222212] [222221] [222221] [222222] [222112] [222121]
[222222] [222122] [222211]
[222212] [222221]
[222222] [222312]
Total fate number: 31 Total fate number: 31
Table 9: Expanded results of four unstable VPC patterns with respect to the results of [9] and [32] (Continued)
Table 10: Thresholds used in the HFPNe model of Figure 6.
Connector Name Connector description Firing threshold
c1(m11, p19) Active MAPK-1 represses the shedding process of ligand-receptor complex 4.3+rand()/10
C2(m5, p22) Active LIN-3/LET-23 dimer represses the expression of lst 0.5+rand()/10
c3(m27, p6) Expressed LST prevents SEM-5 from becoming an active form 0.09+rand()/10
c4(m27, p7) Expressed LST prevents LET-60 from becoming an active form 0.09+rand()/10
c5(m27, p8) Expressed LST prevents MPK-1 from becoming an active form 0.09+rand()/10BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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Fate Patterns (STA) of Tables 8 and 9, i.e., STA is the com-
bination of ST and the pattern extensions.
Simulation procedures
Here, we discuss several considerations of simulation
environment adjustment in order to validate the VPC fate
model and evaluate two rules.
When emulating cell stimulations in in silico experiments,
it is important to adjust the cell to a constant condition
before the stimulation. This condition is usually called a
steady state. For example, simulation time periods of 400
[pt] and 200 [pt] are reserved representing LIN-3 stimula-
tions from AC and hyp7 respectively in the VPC fate
model ([pt] is the virtual time unit of the HFPNe model).
This is because the concentration of the receptor LET-23
will be kept at a steady state after 200 [pt]. The time inter-
val of the stimulations between AC and hyp7 is designed
to investigate respective variation of fate patterns.
Meanwhile, the following is taken into account to emu-
late real environment as well as assessing the robustness
of the model:
(i) The notion of log-normal distribution is intro-
duced. For each process, log-normal distribution is
applied as a system noise. Each standard deviation is
given in the third column in Table 2, where
LSMass(arg1, arg2) denotes the function of log-normal
distribution, arg1 denotes normal reaction speed with-
out noise, and arg2 is the standard deviation denoting
the strength of the noise.
(ii) In the case of lin-15ko mutant, a little temporal dif-
ference between the stimulations of LIN-3 emanating
from hyp7 to each Pn.p is designed to investigate the
influence of ectopic stimuli.
(iii) The key thresholds involved in Ras/MAPK and
LIN-12/Notch signaling pathways are assigned to the
variables, which depend on the function of rand() that
fluctuates randomly between 0.0 and 1.0 (refer to
Table 10). Here, uniform random number generated
by Mersenne Twister random number generator is
used.
We have tried 100, 1,000 and 10,000-run simulation
experiments. For all cases, the results clearly show that
Rule I can generate high fitting score than Rule II. Among
them, since 10,000-run simulation can present the most
precise behaviors of each fate pattern, in this paper we
have concentrated on the 10,000-run simulation results to
investigate the fitting score and variation frequency of 48
genotypes on the VPC fate model. The simulation experi-
ments are carried out on the workstation of Intel Xeon
X5450 (3.0 GHz) processors with 16 Gbytes of memory.
The machine has two CPUs which has four cores per CPU
(number of total processor cores is eight). The theoretical
computational performance is 96 GFLOPS. All simula-
tions were run on Java 1.6 environment. The VPC fate
model will take nearly 100 [sec] for one simulation on
Cell Illustrator with a script-based simulation engine. It
provides detailed visualization of system behaviors. On
the other hand, Cell Illustrator is equipped with a "High-
Speed Simulation Module" specialized in producing sim-
ulation results only. It increases the simulation speed
from 10 to 100 times than the script-based one. Hence,
the 10,000 simulations can be conducted on a day on
average, and the 48 sets can be executed on 48 days on a
single core of a processor. We carried out all simulations
within 6 days on our computing environment. We use the
same model, the same procedures and also the same
parameters to evaluate the fate patterns of all 48 geno-
types with the three simulation targets (refer to Tables 8
and 9).
Results and Discussion
We now exhibit and discuss our simulation results on the
fitting score of predicted fate patterns and the variation
frequency of each appearing fate pattern, especially focus-
ing on the four unstable patterns.
Using the method addressed in the previous sections, we
performed the simulation of the VPC fate model. Tables
10, 11, 12, 13, 14 and Additional file 2 exhibit the simu-
lation results of 48 genotypes. Figures 9, 10, 11 and 12
show the graphs of four unstable patterns (RowID 5, 21,
29, and 45), which depict the variation frequency of each
predicted pattern and the variation distribution based on
simulation results. For example, in Figure 9, the fate pat-
tern [122121] predominantly appeared in the matched
results of JA by using Rule I and Rule II, while the pattern
is regarded as a false pattern because it is not observed in
ST and STA.
From the variation distribution as shown in Figure 9,
[122121] is the fate pattern that can be most easily
observed in in vivo experiments because of the high
appearance. In contrast, [112121] is likely difficult to be
monitored due to the relative low variation frequency.
Each graph comprises three parts of comparison results
obtained from JA, ST and STA (see (a), (b), and (c) in Fig-
ure 9) by using both Rule I and Rule II. In each part, the
variation frequency results of matched patterns are given
on the left side while that of unmatched patterns are
exhibited on the right side. Figures 10, 11 and 12 are built
up in the same way.
From the simulation results, we draw the following con-
clusions:BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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Table 11: Details of the simulation results for RowID 5 in Table 9
RuleI_JA RuleI_ST RuleI_STA
Patterns Num. Patterns Num. Patterns Num. Patterns Num. Patterns Num. Patterns Num.
[112121]X 0 [112121]X 0 [212121]X 0 [112121]X 0 [212123]X 0
[122121]X 9260 [112122]X 0 [212122]X 0 [112122]X 0 [222121]X 0
[212121]X 0 [122121]X 9260 [222121]X 0 [112123]X 0 [222122]X 0
[122122]X 0 [222122]X 0 [122121]X 9260 [312121]X 0
[122122]X 0 [312122]X 0
[212121]X 0 [312123]X 0
[212122]X 0
Total: 9260 (92.6%) Total: 9260 (92.6%) Total: 9260 (92.6%)
[121121] 19 [121121] 19 [121121] 19
[121321] 3 [121321] 3 [121321] 3
[121323] 1 [121323] 1 [121323] 1
[123121] 11 [123121] 11 [123121] 11
[123321] 651 [123321] 651 [123321] 651
[123323] 55 [123323] 55 [123323] 55
Total: 740 (7.4%) Total: 740 (7.4%) Total: 740 (7.4%)
RuleII_JA RuleII_ST RuleII _STA
Patterns Num. Patterns Num. Patterns Num. Patterns Num. Patterns Num. Patterns Num.
[112121]X 11 [112121]X 11 [212121]X 1140 [112121]X 11 [212123]X 0
[122121]X 1289 [112122]X 1 [212122]X 410 [112122]X 1 [222121]X 253
[212121]X 1140 [122121]X 1289 [222121]X 253 [112123]X 0 [222122]X 96
[122122]X 496 [222122]X 96 [122121]X 1289 [312121]X 0
[122122]X 496 [312122]X 0
[212121]X 1140 [312123]X 0
[212122]X 410
Total: 2440 (24.4%) Total: 3696 (36.96%) Total: 3696 (36.96%)
[111122] 1 [211212] 25 [111122] 1 [211222] 2 [111122] 1 [211222] 2
[111221] 1 [211221] 45 [111221] 1 [212111] 77 [111221] 1 [212111] 77
[112111] 1 [211222] 2 [112111] 1 [212112] 318 [112111] 1 [212112] 318
[112112] 2 [212111] 77 [112112] 2 [212211] 95 [112112] 2 [212211] 95
[112122] 1 [212112] 318 [112212] 3 [212212] 400 [112212] 3 [212212] 400
[112212] 3 [212122] 410 [112221] 3 [212221] 449 [112221] 3 [212221] 449
[112221] 3 [212211] 95 [121111] 142 [212222] 64 [121111] 142 [212222] 64
[121111] 142 [212212] 400 [121112] 754 [221111] 54 [121112] 754 [221111] 54
[121112] 754 [212221] 449 [121121] 318 [221112] 265 [121121] 318 [221112] 265
[121121] 318 [212222] 64 [121122] 232 [221121] 110 [121122] 232 [221121] 110
[121122] 232 [221111] 54 [121211] 61 [221122] 70 [121211] 61 [221122] 70
[121211] 61 [221112] 265 [121212] 116 [221211] 18 [121212] 116 [221211] 18
[121212] 116 [221121] 110 [121221] 1084 [221212] 32 [121221] 1084 [221212] 32
[121221] 1084 [221122] 70 [121222] 73 [221221] 426 [121222] 73 [221221] 426
[121222] 73 [221211] 18 [122111] 57 [221222] 45 [122111] 57 [221222] 45
[122111] 57 [221212] 32 [122112] 226 [222111] 11 [122112] 226 [222111] 11
[122112] 226 [221221] 426 [122211] 81 [222112] 33 [122211] 81 [222112] 33
[122122] 496 [221222] 45 [122212] 237 [222211] 8 [122212] 237 [222211] 8
[122211] 81 [222111] 11 [122221] 132 [222212] 23 [122221] 132 [222212] 23
[122212] 237 [222112] 33 [122222] 33 [222221] 28 [122222] 33 [222221] 28
[122221] 132 [222121] 253 [211111] 29 [222222] 11 [211111] 29 [222222] 11
[122222] 33 [222122] 96 [211112] 77 [211112] 77
[211111] 29 [222211] 8 [211121] 17 [211121] 17BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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(1) Rule I gives more genotypes (RowID) with high
fitting scores nearly 100% than Rule II to cover pre-
dicted patterns of three simulation targets. In more
details,
(i) For 44 genotypes (i.e., the genotypes without
unstable fate patterns), each genotype can generate
the fitting score nearly 95%, in which the fitting
scores of 41 genotypes are all 100% (refer to Addi-
tional File 1) by using both Rule I and Rule II. In
other words, our model shows good robustness,
and can produce stable cell fate patterns even we
intentionally add the noise to capture the behav-
iors of the model fluctuations.
(ii) For the left three genotypes of four unstable
fate patterns, lin-15ko mutant (RowID 5) produces
all 92.6% for JA, ST and STA by using Rule I, as
opposed to 24.4% (for JA) and 36.96% (for ST and
STA) by using Rule II; ac-; lin-15ko mutant (RowID
29) produces high coverage of 94.11% (for JA) and
99.86% (for both ST and STA); and ac-; lin-12gf;
lin-15ko double mutants (RowID 45) generates all
100% with both rules for three simulation targets.
(iii) For lin-15; lin-12ko double mutants (RowID
21), the fitting scores in the results of ST and STA
drop to a quite low value below 15% by using
either Rule I or Rule II. This is because P3.p is
allowed to adopt the 1° fate in JA (in silico model),
but is not allowed in ST and STA (in vivo model).
This fact has also been confirmed in the preceding
study [9] that in silico model can faithfully produce
the 1° fate for P3.p. From these observations, it can
[211112] 77 [222212] 23 [211122] 5 [211122] 5
[211121] 17 [222221] 28 [211211] 10 [211211] 10
[211122] 5 [222222] 11 [211212] 25 [211212] 25
[211211] 10 [211221] 45 [211221] 45
Total: 7560 (75.6%) Total: 6304 (63.4%) Total: 6304 (63.4%)
Table 11: X denotes predicted fate pattern, which is also used in Table 12–14.
Table 11: Details of the simulation results for RowID 5 in Table 9 (Continued)
Table 12: Details of the simulation results for RowID 21 in Table 9
RuleI_JA RuleI_ST RuleI_STA
Patterns Num. Patterns Num. Patterns Num. Patterns Num. Patterns Num. Patterns Num.
[112121]X 145 [212121]X 1440 [212121]X 1440 [222121]X 0 [212121]X 1440 [222121]X 0
[122121]X 6544 [212122]X 0 [222122]X 0 [212122]X 0 [222122]X 0
Total: 8129 (81.29%) Total: 1440 (14.4%) Total: 1440 (14.4%)
[112111] 5 [122111] 8 [112111] 5 [121212] 1339 [112111] 5 [121212] 1339
[121111] 38 [112121] 145 [122111] 8 [112121] 145 [122111] 8
[121121] 481 [121111] 38 [122121] 6544 [121111] 38 [122121] 6544
[121212] 1339 [121121] 481 [121121] 481
Total: 1871 (18.71%) Total: 8560 (85.6%) Total: 8560 (85.6%)
RuleII_JA RuleII_ST RuleII_STA
Patterns Num. Patterns Num. Patterns Num. Patterns Num. Patterns Num. Patterns Num.
[112121]X 0 [212121]X 1440 [212121]X 1440 [222121]X 0 [212121]X 1440 [222121]X 0
[122121]X 7221 [212122]X 0 [222122]X 0 [212122]X 0 [222122]X 0
Total: 8661 (86.61%) Total: 1440 (14.4%) Total: 1440 (14.4%)
[121212] 1339 [121212] 1339 [122121] 7221 [121212] 1339 [122121] 7221
Total: 1339 (13.39%) Total: 8560 (85.6%) Total: 8560 (85.6%)BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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Table 13: Details of the simulation results for RowID 29 in Table 9
RuleI_JA RuleI_ST RuleI_STA
Patterns Num. Patterns Num. Patterns Num. Patterns Num. Patterns Num. Patterns Num.
[111111]X 0 [111111]X 0 [211112]X 0 [111111]X 0 [211111]X 0
[111112]X 0 [111112]X 0 [211121]X 0 [111112]X 0 [211112]X 0
[111121]X 0 [111121]X 0 [211122]X 0 [111121]X 0 [211121]X 0
[111211]X 0 [111122]X 0 [211211]X 0 [111122]X 0 [211122]X 0
[111212]X 0 [111211]X 0 [211212]X 0 [111211]X 0 [211211]X 0
[111221]X 0 [111212]X 0 [211221]X 0 [111212]X 0 [211212]X 0
[112111]X 0 [111221]X 0 [211222]X 0 [111221]X 0 [211221]X 0
[112112]X 0 [111222]X 0 [212111]X 0 [111222]X 0 [211222]X 0
[112121]X 0 [112111]X 0 [212112]X 0 [112111]X 0 [212111]X 0
[112211]X 0 [112112]X 0 [212121]X 0 [112112]X 0 [212112]X 0
[112212]X 0 [112121]X 0 [212122]X 0 [112121]X 0 [212121]X 0
[121111]X 0 [112122]X 0 [212211]X 0 [112122]X 0 [212122]X 0
[121112]X 0 [112211]X 0 [212212]X 0 [112211]X 0 [212211]X 0
[121121]X 120 [112212]X 0 [212221]X 0 [112212]X 0 [212212]X 0
[121211]X 0 [112221]X 0 [212222]X 0 [112221]X 0 [212221]X 0
[121212]X 0 [112222]X 0 [221111]X 0 [112222]X 0 [212222]X 0
[121221]X 4393 [121111]X 0 [221112]X 0 [121111]X 0 [221111]X 0
[122111]X 0 [121112]X 0 [221121]X 0 [121112]X 0 [221112]X 0
[122112]X 0 [121121]X 120 [221122]X 0 [121121]X 120 [221121]X 0
[122121]X 4898 [121122]X 0 [221211]X 0 [121122]X 0 [221122]X 0
[211111]X 0 [121211]X 0 [221212]X 0 [121131]X 0 [221211]X 0
[211112]X 0 [121212]X 0 [221221]X 0 [121211]X 0 [221212]X 0
[211121]X 0 [121221]X 4393 [221222]X 0 [121212]X 0 [221221]X 0
[211211]X 0 [121222]X 0 [222111]X 0 [121221]X 4393 [221222]X 0
[211212]X 0 [122111]X 0 [222112]X 0 [121222]X 0 [222111]X 0
[211221]X 0 [122112]X 0 [222121]X 0 [122111]X 0 [222112]X 0
[212111]X 0 [122121]X 4898 [222122]X 0 [122112]X 0 [222121]X 0
[212112]X 0 [122122]X 0 [222211]X 0 [122121]X 4898 [222122]X 0
[212121]X 0 [122211]X 0 [222212]X 0 [122122]X 0 [222211]X 0
[212211]X 0 [122212]X 0 [222221]X 0 [122211]X 0 [222212]X 0
[212212]X 0 [122221]X 575 [222222]X 0 [122212]X 0 [222221]X 0
[122222]X 0 [122221]X 575 [222222]X 0
[211111]X 0 [122222]X 0
Total: 9411 (94.11%) Total: 9986 (99.86%) Total: 9986 (99.86%)
[121223] 14 [122221] 575 [121223] 14 [121223] 14
Total: 589 (5.89%) Total: 14 (0.14%) Total: 14 (0.14%)
RuleII_JA RuleII_ST RuleII_STA
Patterns Num. Patterns Num. Patterns Num. Patterns Num. Patterns Num. Patterns Num.
[111111]X 0 [111111]X 0 [211112]X 7 [111111]X 0 [211111]X 5
[111112]X 0 [111112]X 0 [211121]X 12 [111112]X 0 [211112]X 7
[111121]X 1 [111121]X 1 [211122]X 5 [111121]X 1 [211121]X 12
[111211]X 0 [111122]X 0 [211211]X 38 [111122]X 0 [211122]X 5
[111212]X 0 [111211]X 0 [211212]X 110 [111211]X 0 [211211]X 38
[111221]X 3 [111212]X 0 [211221]X 62 [111212]X 0 [211212]X 110
[112111]X 0 [111221]X 3 [211222]X 15 [111221]X 3 [211221]X 62
[112112]X 1 [111222]X 0 [212111]X 47 [111222]X 0 [211222]X 15
[112121]X 14 [112111]X 0 [212112]X 124 [112111]X 0 [212111]X 47
[112211]X 0 [112112]X 1 [212121]X 1214 [112112]X 1 [212112]X 124
[112212]X 4 [112121]X 14 [212122]X 405 [112121]X 14 [212121]X 1214
[121111]X 5 [112122]X 3 [212211]X 125 [112122]X 3 [212122]X 405BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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[121112]X 12 [112211]X 0 [212212]X 533 [112211]X 0 [212211]X 125
[121121]X 98 [112212]X 4 [212221]X 448 [112212]X 4 [212212]X 533
[121211]X 238 [112221]X 2 [212222]X 82 [112221]X 2 [212221]X 448
[121212]X 850 [112222]X 1 [221111]X 3 [112222]X 1 [212222]X 82
[121221]X 1271 [121111]X 5 [221112]X 9 [121111]X 5 [221111]X 3
[122111]X 12 [121112]X 12 [221121]X 46 [121112]X 12 [221112]X 9
[122112]X 70 [121121]X 98 [221122]X 36 [121121]X 98 [221121]X 46
[122121]X 1263 [121122]X 54 [221211]X 79 [121122]X 54 [221122]X 36
[211111]X 5 [121211]X 238 [221212]X 296 [121131]X 0 [221211]X 79
[211112]X 7 [121212]X 850 [221221]X 441 [121211]X 238 [221212]X 296
[211121]X 12 [121221]X 1271 [221222]X 88 [121212]X 850 [221221]X 441
[211211]X 38 [121222]X 246 [222111]X 3 [121221]X 1271 [221222]X 88
[211212]X 110 [122111]X 12 [222112]X 16 [121222]X 246 [222111]X 3
[211221]X 62 [122112]X 70 [222121]X 227 [122111]X 12 [222112]X 16
[212111]X 47 [122121]X 1263 [222122]X 103 [122112]X 70 [222121]X 227
[212112]X 124 [122122]X 511 [222211]X 6 [122121]X 1263 [222122]X 103
[212121]X 1214 [122211]X 100 [222212]X 45 [122122]X 511 [222211]X 6
[212211]X 125 [122212]X 403 [222221]X 28 [122211]X 100 [222212]X 45
[212212]X 533 [122221]X 138 [222222]X 10 [122212]X 403 [222221]X 28
[122222]X 32 [122221]X 138 [222222]X 10
[211111]X 5 [122222]X 32
Total: 6119 (61.19%) Total: 10000 (100%) Total: 10000 (100%)
[112122] 3 [122211] 100
[112221] 2 [122212] 403 [212122] 405 [221121] 46 [221222] 88 [222211] 6
[112222] 1 [122221] 138 [212221] 448 [221122] 36 [222111] 3 [222212] 45
[121122] 54 [122222] 32 [212222] 82 [221211] 79 [222112] 16 [222221] 28
[121222] 246 [211122] 5 [221111] 3 [221212] 296 [222121] 227 [222222] 10
[122122] 511 [211222] 15 [221112] 9 [221221] 441 [222122] 103
Total: 3881 (38.81%)
Table 13: Details of the simulation results for RowID 29 in Table 9 (Continued)
Table 14: Details of the simulation results for RowID 45 in Table 9
RuleI_JA RuleI_ST RuleI_STA
Patterns Num. Patterns Num. Patterns Num. Patterns Num. Patterns Num. Patterns Num.
[111111]X 0 [111111]X 0 [211122]X 0 [111111]X 0 [211122]X 0
[111112]X 0 [111112]X 0 [211211]X 0 [111112]X 0 [211211]X 0
[111121]X 0 [111121]X 0 [211212]X 0 [111121]X 0 [211212]X 0
[111211]X 2 [111122]X 0 [211221]X 0 [111122]X 0 [211221]X 0
[111212]X 32 [111211]X 2 [211222]X 0 [111211]X 2 [211222]X 0
[111221]X 0 [111212]X 32 [212111]X 108 [111212]X 32 [212111]X 108
[112111]X 6 [111221]X 0 [212112]X 0 [111221]X 0 [212112]X 0
[112112]X 0 [111222]X 0 [212121]X 1336 [111222]X 0 [212121]X 1336
[112121]X 115 [112111]X 6 [212122]X 0 [112111]X 6 [212122]X 0
[112211]X 0 [112112]X 0 [212211]X 0 [112112]X 0 [212211]X 0
[112212]X 0 [112121]X 115 [212212]X 0 [112121]X 115 [212212]X 0
[121111]X 0 [112122]X 0 [212221]X 0 [112122]X 0 [212221]X 0
[121112]X 0 [112211]X 0 [212222]X 0 [112211]X 0 [212222]X 0
[121121]X 94 [112212]X 0 [221111]X 0 [112212]X 0 [221111]X 0
[121211]X 62 [112221]X 0 [221112]X 0 [112221]X 0 [221112]X 0
[121212]X 1430 [112222]X 0 [221121]X 0 [112222]X 0 [221121]X 0
[121221]X 2795 [121111]X 0 [221122]X 0 [121111]X 0 [221122]X 0
[122111]X 1 [121112]X 0 [221211]X 0 [121112]X 0 [221123]X 0
[122112]X 0 [121121]X 94 [221212]X 0 [121121]X 94 [221211]X 0
[122121]X 4019 [121122]X 0 [221221]X 0 [121122]X 0 [221212]X 0
[211111]X 0 [121211]X 62 [221222]X 0 [121211]X 62 [221221]X 0BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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[211112]X 0 [121212]X 1430 [222111]X 0 [121212]X 1430 [221222]X 0
[211121]X 0 [121221]X 2795 [222112]X 0 [121221]X 2795 [221223]X 0
[211211]X 0 [121222]X 0 [222121]X 0 [121222]X 0 [221321]X 0
[211212]X 0 [122111]X 1 [222122]X 0 [122111]X 1 [221322]X 0
[211221]X 0 [122112]X 0 [222211]X 0 [122112]X 0 [221323]X 0
[212111]X 108 [122121]X 4019 [222212]X 0 [122121]X 4019 [222111]X 0
[212112]X 0 [122122]X 0 [222221]X 0 [122122]X 0 [222112]X 0
[212121]X 1336 [122211]X 0 [222222]X 0 [122211]X 0 [222121]X 0
[212211]X 0 [122212]X 0 [122212]X 0 [222122]X 0
[212212]X 0 [122221]X 0 [122221]X 0 [222211]X 0
[122222]X 0 [122222]X 0 [222212]X 0
[211111]X 0 [211111]X 0 [222221]X 0
[211112]X 0 [211112]X 0 [222222]X 0
[211121]X 0 [211121]X 0 [222312]X 0
Total: 10000 (100%) Total: 10000 (100%) Total: 10000 (100%)
RuleII_JA RuleII_ST RuleII_STA
Patterns Num. Patterns Num. Patterns Num. Patterns Num. Patterns Num. Patterns Num.
[111111]X 0 [111111]X 0 [211122]X 0 [111111]X 0 [211122]X 0
[111112]X 0 [111112]X 0 [211211]X 0 [111112]X 0 [211211]X 0
[111121]X 0 [111121]X 0 [211212]X 0 [111121]X 0 [211212]X 0
[111211]X 0 [111122]X 0 [211221]X 0 [111122]X 0 [211221]X 0
[111212]X 0 [111211]X 0 [211222]X 0 [111211]X 0 [211222]X 0
[111221]X 0 [111212]X 0 [212111]X 0 [111212]X 0 [212111]X 0
[112111]X 0 [111221]X 0 [212112]X 0 [111221]X 0 [212112]X 0
[112112]X 0 [111222]X 0 [212121]X 1444 [111222]X 0 [212121]X 1444
[112121]X 0 [112111]X 0 [212122]X 0 [112111]X 0 [212122]X 0
[112211]X 0 [112112]X 0 [212211]X 0 [112112]X 0 [212211]X 0
[112212]X 0 [112121]X 0 [212212]X 0 [112121]X 0 [212212]X 0
[121111]X 0 [112122]X 0 [212221]X 0 [112122]X 0 [212221]X 0
[121112]X 0 [112211]X 0 [212222]X 0 [112211]X 0 [212222]X 0
[121121]X 0 [112212]X 0 [221111]X 0 [112212]X 0 [221111]X 0
[121211]X 0 [112221]X 0 [221112]X 0 [112221]X 0 [221112]X 0
[121212]X 1462 [112222]X 0 [221121]X 0 [112222]X 0 [221121]X 0
[121221]X 2859 [121111]X 0 [221122]X 0 [121111]X 0 [221122]X 0
[122111]X 0 [121112]X 0 [221211]X 0 [121112]X 0 [221123]X 0
[122112]X 0 [121121]X 0 [221212]X 0 [121121]X 0 [221211]X 0
[122121]X 4235 [121122]X 0 [221221]X 0 [121122]X 0 [221212]X 0
[211111]X 0 [121211]X 0 [221222]X 0 [121211]X 0 [221221]X 0
[211112]X 0 [121212]X 1462 [222111]X 0 [121212]X 1462 [221222]X 0
[211121]X 0 [121221]X 2859 [222112]X 0 [121221]X 2859 [221223]X 0
[211211]X 0 [121222]X 0 [222121]X 0 [121222]X 0 [221321]X 0
[211212]X 0 [122111]X 0 [222122]X 0 [122111]X 0 [221322]X 0
[211221]X 0 [122112]X 0 [222211]X 0 [122112]X 0 [221323]X 0
[212111]X 0 [122121]X 4235 [222212]X 0 [122121]X 4235 [222111]X 0
[212112]X 0 [122122]X 0 [222221]X 0 [122122]X 0 [222112]X 0
[212121]X 1444 [122211]X 0 [222222]X 0 [122211]X 0 [222121]X 0
[212211]X 0 [122212]X 0 [122212]X 0 [222122]X 0
[212212]X 0 [122221]X 0 [122221]X 0 [222211]X 0
[122222]X 0 [122222]X 0 [222212]X 0
[211111]X 0 [211111]X 0 [222221]X 0
[211112]X 0 [211112]X 0 [222222]X 0
[211121]X 0 [211121]X 0 [222312]X 0
Total: 10000 (100%) Total: 10000 (100%) Total: 10000 (100%)
Table 14: Details of the simulation results for RowID 45 in Table 9 (Continued)BMC Systems Biology 2009, 3:42 http://www.biomedcentral.com/1752-0509/3/42
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The simulation results of lin-15ko mutants (RowID 5) Figure 9
The simulation results of lin-15ko mutants (RowID 5).
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The simulation results of lin-12gf; lin-15ko double mutants (RowID 21) Figure 10
The simulation results of lin-12gf; lin-15ko double mutants (RowID 21).
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The simulation results of ac- and lin-15ko mutant (RowID 29) Figure 11
The simulation results of ac- and lin-15ko mutant (RowID 29).
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The simulation results of ac- and lin-12gf; lin-15ko double mutants (RowID 45) Figure 12
The simulation results of ac- and lin-12gf; lin-15ko double mutants (RowID 45).
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be considered that P3.p has a greater possibility to
adopt the 1° fate, if the number of animals for the
in vivo experiments can be increased to 10,000. In
this way, the fitting score can be exactly increased
to exceed more than 81% from the present 15%.
(2) For lin-15ko (RowID 5) and ac-;lin-15ko (RowID
29) genotypes, we can see that nearly 10% patterns in
JA, ST and STA are not matched (refer to Tables 11 and
13). These patterns still have the possibility to be
examined in in vivo experiments by means of enlarging
animal population.
(3) Since the experiment data about hybrid lineages
has not been taken into account as we have pointed
out, we interpret these uninterpretable lineages to
three fate pattern extensions as listed in the column of
STA which includes more extensive possible fate pat-
terns than ST. In the simulation results, the results of
lin-12ko mutant (RowID 9) interest us (refer to the
Additional file 1). We can find that the fate pattern
[331133] appeared in our simulation results of STA,
which is the extended fate pattern from the hybrid lin-
eage data exhibited in [32]. This hybrid lineage gives
new insights on the imprecise fate decision and the
fate specification mechanisms when a system comes
close to a certain threshold.
Taking these observations together, we conclude that Rule
I relying on the temporal interval can be considered more
reasonable and proper in evaluating the VPC fate specifi-
cation than Rule II.
Conclusion
The contribution of this paper is a novel method of mod-
eling and simulating biological systems with the use of
model checking approach on the hybrid functional Petri
net with extension. A quantitative HFPNe model for the
vulval development is constructed based on the literature.
Then we employ two major biological fate determination
rules to the quantitative model. These two rules are inves-
tigated by applying model checking approach in a quanti-
tative manner. Three simulation targets of this model are
considered: The first one is the fate patterns obtained by
improving the qualitative method of Fisher et al. [9]; the
second target is the fate patterns summarized by Sternberg
and Horvitz [32]; and the last one is derived from the bio-
logical experiments in [32] including the hybrid lineage
data. We have performed 480,000 simulations on the
quantitative HFPNe model by using Cell Illustrator. We
have examined the consistency and the correctness of the
model, and evaluated the two rules of VPC fate specifica-
tion. We consider that this computational experiment and
the biological evaluation could not be easily put into prac-
tice without the HFPNe modeling method and the func-
tions of Cell Illustrator, especially, the "High-Speed
Simulation Module". Finally, in silico simulation results
have been given in the form of the fitting score and the
variation frequency of each pattern. We have discussed the
results and summarized several plausible explanations.
Appendix: Abbreviations
AC: (gonadal anchor cell); ac-: (absence of an anchor
cell); EGFR: (the epidermal growth factor receptor);
HFPNe: (hybrid functional Petri net with extension); JA:
(fate patterns obtained with our extended method from
the discrete model of Fisher et al. [9]); LBS: (LAG-1 bind-
ing site); lst: (lateral signal target); MAPK: (mitogen-acti-
vated protein kinases); ST: (fate patterns summarized by
Sternberg and Horvitz [32]); STA: (fate pattern combina-
tions consisting of ST and the pattern extensions);
VPC:(vulval precursor cell); synMuv: (synthetic Multi-
vulva);
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